{"filings":[{"id":1583356,"accession_number":"0001193125-26-301052","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-07-10T21:29:46+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma raises $50M in private placement led by Cormorant and Columbia Threadneedle","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $50M from sale of 1,418,071 shares at $33.21/share and pre-funded warrants for 87,500 shares at $33.209.","Private placement led by Cormorant Asset Management and Columbia Threadneedle Investments; expected to close July 13, 2026.","Net proceeds to fund clinical development and general corporate purposes; CEO cites upcoming Phase 2 CSU data from Ascendant Health expected by Q3 2026.","Board granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao-Lee Lin, with time and performance-based vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834039,"accession_number":"0001193125-26-255479","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-06-03T20:16:49+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cue Biopharma stockholders approve 2026 stock plan and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant share issuance from May 2026 licensing transaction approved (1.78M For, 113K Against).","2026 Stock Incentive Plan approved with 1.26M For, 632K Against, 2,687 Abstain.","Adjournment proposal approved (1.30M For, 582K Against); not needed as main proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":807436,"accession_number":"0001193125-26-253709","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-06-02T20:45:51+00:00","items":["5.02","8.01"],"status":"ready","headline":"Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignations of directors Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen effective May 29, 2026.","Sumita Ray appointed Chief Legal & Compliance Officer and Corporate Secretary on June 1, 2026.","Michael Meluzio appointed VP, Principal Accounting Officer on June 1, 2026.","Daniel Camardo and Viola Meehan appointed as directors on May 30, 2026; board reduced from seven to five."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443038,"accession_number":"0001193125-26-224101","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-05-14T20:19:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.","Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.","Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.","Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.","Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":5686000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94353,"accession_number":"0001193125-26-198588","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.","Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.","New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.","Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.","Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94352,"accession_number":"0001193125-26-168907","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.","Common stock begins trading post-split on April 24 under symbol CUE; new CUSIP 22978P205.","Reverse split aims to meet Nasdaq minimum bid price requirement, as disclosed in proxy statement.","No change in authorized shares ($0.001 par); options and warrants proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94351,"accession_number":"0001193125-26-152826","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cue Biopharma stockholders approve reverse stock split with ratio 1:30 to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot to the Board.","Ratified RSM US LLP as independent auditor for FY2026 with 58,982,168 votes for.","Approved non-binding advisory say-on-pay with 31,388,709 for, 4,239,819 against.","Approved reverse stock split amendment at 51,011,729 for; ratio range 1-for-30 to 1-for-50 at Board's discretion.","Prior CEO Usman Azam resigned March 26, 2026; votes for him were disregarded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94350,"accession_number":"0001193125-26-144569","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.","Milestone triggers $7.5M payment to Cue Biopharma, expected in May 2026.","Collaboration targets differentiated B cell depletion molecules including CUE-501."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106636,"accession_number":"0001193125-26-128993","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Usman Azam resigned as President, CEO and Board member effective March 26, 2026.","Lucinda Warren, previously CFO and CBO, appointed Interim President and CEO effective March 27, 2026; retains CFO and CBO roles.","Warren's base salary $525,000; eligible for 45% target bonus and up to 1.0% stock option upon financing milestone.","Azam severance: lump sum $232,500 (3 months salary plus 25% of 2026 target bonus) plus up to 12 months COBRA.","Warren receives $10,000/month supplemental until new CEO hired or 12-month anniversary, with lump sum if earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106635,"accession_number":"0001193125-26-108292","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.","Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.","R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).","Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.","Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106634,"accession_number":"0001193125-26-056983","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cue Biopharma sets 2026 annual meeting for April 13; shareholder deadlines on Feb 28.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting date: April 13, 2026.","Shareholder proposals under Rule 14a-8 must be received by February 28, 2026.","Director nominations and other business also due by February 28, 2026 per Bylaws and Rule 14a-19.","Proxies may exercise discretionary voting on late proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106633,"accession_number":"0001193125-26-047717","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints CBO Lucinda Warren as CFO effective Feb 9, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucinda Warren, previously CBO, named Chief Financial & Business Officer; assumes principal financial/accounting officer duties.","Warren had been CBO since Sept 2024; prior VP Business Development at Johnson & Johnson (2014-2024).","No additional compensation or changes to her employment agreement for the CFO role.","No family relationships with directors/officers; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122964,"accession_number":"0001193125-25-326925","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.","Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.","Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.","Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122963,"accession_number":"0001193125-25-292093","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cue Biopharma posts updated corporate presentation on website; no specific new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made an updated corporate presentation available on its website on November 24, 2025.","The presentation was furnished as Exhibit 99.1 to the 8-K filing.","No financial results, material transactions, or forward-looking guidance were included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122962,"accession_number":"0001193125-25-289713","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma CMO Matteo Levisetti to depart Nov 28; gets $556,838 severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Matteo Levisetti will terminate employment effective November 28, 2025.","Severance includes lump sum of $556,837.60 (nine months base salary plus prorated 2025 bonus).","COBRA premiums paid by company for up to nine months post-separation if elected.","Payment conditioned on execution and nonrevocation of a separation and release agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122961,"accession_number":"0001193125-25-277468","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).","Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.","Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.","CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.","R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5524000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122960,"accession_number":"0001193125-25-268135","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.","Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.","Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.","IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.","Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139667,"accession_number":"0000950130-25-000140","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.","Azam receives base salary $620,000, bonus target 50% of base, stock options for 2.25M shares (1.875M time-based + 375K performance-based).","Passeri receives lump sum severance of $838,750, 12-month equity vesting acceleration, and COBRA for 18 months.","Passeri advisor agreement: stock option for 375K shares tied to financing milestone, term through March 30, 2026, with continued equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139666,"accession_number":"0000950170-25-107268","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.","Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.","Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.","CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.","Raised ~$20M via public offering; cash position $27.5M at June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3374000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139665,"accession_number":"0000950170-25-092168","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cue Biopharma reduces monthly rent 37% and extends Boston lease to April 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monthly rent cut from $235,884 to $147,546, effective June 30, 2025.","Lease term extended by two years to April 14, 2028, from prior April 14, 2026.","Landlord granted a partial rent credit of $44,169 for June 2025.","Rent subject to a 4% increase on April 15, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157247,"accession_number":"0000950170-25-084279","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.","Jill Broadfoot appointed to board and Audit Committee chair; granted option to purchase 48,800 shares.","Authorized shares of capital stock increased from 210M to 310M; common stock from 200M to 300M.","Stockholders approved 2025 Stock Incentive Plan (13.85M for, 2.01M against); also elected all director nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157246,"accession_number":"0000950170-25-069124","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.","Announced Boehringer Ingelheim collaboration for CUE-501: $12M upfront + up to $345M milestones.","Raised ~$20M gross in follow-on capital raise; received $12M BI upfront in April 2025.","Regained worldwide rights to lead autoimmune program CUE-401; virtual event May 15 with KOLs.","R&D spend $8.5M vs $10.2M YoY; G&A flat at $4.2M; cash $13.1M at Mar 31."],"consensus_eps_estimate":-4.6459,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":421000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157245,"accession_number":"0001193125-25-081592","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.","Net proceeds estimated at $18M; closing expected April 16, 2025.","Preliminary cash and cash equivalents of $13.1M as of March 31, 2025 (unaudited).","Including $12M upfront from Boehringer Ingelheim deal, cash runway extended into Q2 2026.","Offering includes pre-funded warrants for 11.47M shares at $0.001 exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157244,"accession_number":"0001193125-25-080277","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.","BI gets exclusive worldwide license to develop and commercialize CUE-501 and other B cell depletion molecules.","Cue prohibited from developing or commercializing any B cell depletion molecules during the 4-year research term.","BI will pay research support during research term; royalties on net sales subject to standard reductions.","Amendment with Einstein College of Medicine allows sublicense to BI and adjusts upstream payment obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175616,"accession_number":"0000950170-25-047678","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.","Collaboration revenue $1.6M in Q4 vs $1.8M a year ago; full year rev $9.3M from Ono Pharma deal.","R&D spend cut to $7.2M (Q4) from $10.9M; cash and equivalents $22.5M as of Dec 31, 2024.","Regained worldwide rights to CUE-401 (autoimmune lead); prioritizing autoimmune over oncology.","Appointed Lucinda Warren (CBO), Dr. Daniel Baker (Interim CDO), Dr. Pasha Sarraf (Board)."],"consensus_eps_estimate":-4.6459,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":421000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175615,"accession_number":"0000950170-25-037885","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints Pasha Sarraf to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pasha Sarraf appointed to board on March 10, 2025.","Granted option to purchase 48,800 shares vesting over three years.","Compensation per Company's Director Compensation Policy.","Entered standard indemnification agreement for director service.","No arrangements or transactions between Sarraf and Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192565,"accession_number":"0000950170-24-127004","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.","Cash $32.4M, expected to fund operations into Q4 2025; $12M public offering priced in quarter.","CUE-101 + KEYTRUDA Phase 1 data: 46% ORR, 91.3% 12-month OS, 21.8-month mOS in 1L HPV+ HNSCC.","CUE-102 monotherapy: 67% DCR in late-stage pancreatic cancer; favorable tolerability with no DLTs.","Appointed Lucinda Warren as Chief Business Officer; preclinical autoimmune programs advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":7711000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192564,"accession_number":"0000950170-24-113520","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cue Biopharma stockholders approve doubling authorized common stock to 200M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 110M to 210M total, common from 100M to 200M.","Shareholders voted 29,291,818 for, 7,409,258 against, 499,006 abstain at Oct 8, 2024 special meeting.","Certificate of Amendment filed with Delaware Secretary of State on October 8, 2024.","No specific issuance plan disclosed; amendment provides flexibility for future capital needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192563,"accession_number":"0000950170-24-112887","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cue Biopharma amends SVB credit agreement, eliminates $20M cash reserve requirement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment dated Oct 2, 2024 removes $20M minimum cash requirement from SVB loan agreement.","New covenant requires Cue to maintain at SVB lesser of $20M or 100% of consolidated cash.","No Event of Default occurred; representations and warranties reaffirmed as of effective date.","All other terms of the Loan and Security Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209032,"accession_number":"0001193125-24-227977","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.","Net proceeds estimated at $10.7M after underwriting discounts and expenses.","Oppenheimer & Co. is sole book-running manager; closing expected September 30, 2024.","Cash runway extended into fourth quarter of 2025, based on current plans.","Warrants: pre-funded exercisable at $0.001, common stock warrants at $0.50, expire in five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209031,"accession_number":"0000950170-24-102851","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Michael J. Fox resigns from Cue Biopharma board effective Aug 28, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael J. Fox resigned as director and from all board committees on August 28, 2024.","Resignation not related to any disagreement with the company on operations, policies, or practices.","No replacement director has been announced or named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209030,"accession_number":"0000950170-24-098032","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cue Biopharma receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on August 15, 2024 for failure to meet minimum bid price of $1.00 for 30 consecutive business days.","Has 180 calendar days (until Feb 11, 2025) to regain compliance by having bid price ≥$1.00 for 10 consecutive business days.","If not compliant, may qualify for another 180-day period, subject to meeting other listing standards.","Company will evaluate options including potential reverse stock split to cure deficiency.","No assurance of regaining compliance; stock remains listed pending cure or potential delisting appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209029,"accession_number":"0000950170-24-086476","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma restructures, cuts workforce 25%, extends cash runway to mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces workforce by ~25% across R&D and G&A; CEO Daniel Passeri takes 50% salary reduction, execs forgo 2023 bonuses.","Prioritizes autoimmune programs CUE-401 (partnered with Ono) and CUE-501; retains oncology CUE-101/102 Phase 1 data maturation.","Projects FY2025 annual cash burn of ~$30M, an ~25% reduction in operating expenses.","Expects extended cash runway into mid-2025; actively pursuing partnerships for oncology programs.","Restructuring effective July 24, 2024; aims to reduce capital requirements and strengthen operational efficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226879,"accession_number":"0000950170-24-070566","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Cue Biopharma appoints Michael J. Fox to board; grants 48,800-share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael J. Fox appointed to Board and Compensation Committee effective June 5, 2024.","Received option to purchase 48,800 shares vesting over three years (1/3 at one year, then quarterly).","Stockholders elected all 7 director nominees; Passeri received 13,099,740 for, 765,119 withheld.","Ratified RSM US LLP as auditor for FY2024 with 32,418,349 for, 1,635,231 against.","Non-binding say-on-pay passed with 11,745,009 for, 1,924,707 against, 20,311,373 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226878,"accession_number":"0000950170-24-056848","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.","Cash and equivalents $41.0M at March 31, expected to fund operations into Q1 2025.","CUE-101 abstract accepted for oral presentation at ASCO 2024; FDA meeting on registrational path.","Preclinical CUE-401 (with Ono) and new CUE-500 series for autoimmune/inflammatory diseases.","R&D expenses $10.2M, G&A $4.2M; net loss $12.3M for the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1717000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280484,"accession_number":"0001193125-23-235298","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma director Aaron Fletcher resigns from board effective Oct 9, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Fletcher notified Cue Biopharma of resignation from Board and all committees.","Resignation effective October 9, 2023, is not due to any disagreement with the Company.","No replacement or successor named; board size adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299074,"accession_number":"0001193125-23-164491","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cue Biopharma announces results of 2023 Annual Meeting; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected; Daniel Passeri received 11,665,042 for, 2,353,834 withheld.","Ratification of RSM US LLP as auditor: 30,764,366 for, 105,334 against, 886,546 abstain.","Say-on-pay approved with 11,079,655 for, 2,042,073 against, 897,148 abstain.","Stockholders recommended annual say-on-pay votes; company will hold votes every year.","Broker non-votes ranged from 17,737,370 across proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299073,"accession_number":"0000950170-23-014246","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma appoints Pamela Garzone to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pamela Garzone appointed to board effective April 19, 2023, following recommendation of committee.","Received option to purchase 40,000 shares vesting over three years.","Compensation per Director Compensation Policy; standard indemnification agreement.","No reportable transactions or arrangements with other persons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299072,"accession_number":"0000950170-23-012492","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cue Biopharma appoints Patrick Verheyen to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Verheyen appointed to the Board on April 11, 2023.","Granted option to purchase 40,000 shares vesting over 3 years.","Compensation per Director Compensation Policy filed as Exhibit 10.1.","No reportable transactions or arrangements with any other person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319237,"accession_number":"0000950170-23-007304","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Howson to retire from Cue Biopharma board at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Howson informed the board on March 7, 2023 of her retirement.","She will not stand for re-election at the 2023 annual meeting.","Retirement is not due to any disagreement with company operations.","Howson currently serves on Compensation and Governance committees.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337449,"accession_number":"0001193125-22-285792","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Cue Biopharma raises $30M in PIPE financing; sells shares, pre-funded warrants, and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $30M; net proceeds ~$28.2M after fees.","Issued 7,656,966 shares, pre-funded warrants for 1,531,440 shares, and warrants for up to 9,188,406 shares at $3.265/unit.","Warrant exercise price $3.93, exercisable for 5 years; pre-funded warrants exercisable indefinitely.","Proceeds to fund CUE-101 clinical development, business development, working capital.","Closing expected Nov 16, 2022; Piper Sandler and Public Ventures as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372835,"accession_number":"0001193125-22-178755","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cue Biopharma Director Cameron Gray Resigns from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cameron Gray notified Cue Biopharma of his resignation as a Board member on June 16, 2022.","Gray also resigned from all board committees, effective immediately.","The resignation was not related to any disagreement with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372834,"accession_number":"0001193125-22-171921","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cue Biopharma reports 2022 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected (Driscoll, Fletcher, Gray, Howson, Kiener, Morich, Passeri).","Ratification of RSM US LLP as independent auditor for FY 2022 approved with 26,125,468 votes for.","Broker non-votes of 14,293,960 on director elections; no other proposals were voted on.","Meeting held June 9, 2022; results filed on June 10, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391653,"accession_number":"0001193125-22-089787","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cue Biopharma signs 4-year license for Boston office/lab space; monthly rent $200,700","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease covers ~13,000 sq ft at 40 Guest Street, Boston; term April 15, 2022 to April 14, 2026.","Monthly base rent $200,700 first year, escalating 4% annually: Year2 $208,728, Year3 $217,077, Year4 $225,760.","Initial payment due at signing: $652,220.40 plus parking fees (20 spaces).","Company plans to relocate corporate headquarters to the Premises in April 2022.","Licensor (MIL 40G) provides services including gases, chemicals, equipment, IT, security."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391652,"accession_number":"0001193125-22-046662","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Cue Biopharma enters $20M SVB loan facility with tranche A of $10M available immediately","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche A of $10M funded at closing; two additional tranches up to $5M each contingent on CUE-101 data and equity proceeds.","Interest rate: prime plus 2.25% (floor 5.5%); repayment begins June 2023 or Dec 2023 if tranche B advanced; maturity Dec 2025.","Prepayment premium: 3% within 1yr, 2% 1-2yr, 1% after 2yr; final payment fee 5% of original principal.","Secured by substantially all assets except IP (negative pledge); requires cash at SVB equal to lesser of all cash or 110% of obligations.","Standard events of default; default triggers 3% rate increase and acceleration of all obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409882,"accession_number":"0001193125-21-328969","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cue Biopharma presents at Stifel Healthcare Conference; corporate slides attached","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation on Nov 15, 2021 at Stifel Healthcare Conference.","Corporate slides attached as exhibit; no specific data points provided in filing text.","No financial or clinical updates disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409881,"accession_number":"0001193125-21-289829","cik":1645460,"company_name":"Cue Biopharma, Inc.","ticker":"CUE","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cue Biopharma enters $80M at-the-market equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company enters Open Market Sale Agreement with Jefferies LLC to sell up to $80M of common stock at-the-market.","Prior $40M ATM agreement with Stifel terminated; $33.4M in gross proceeds realized from 2,099,700 shares sold.","Jefferies will receive 3.0% commission on gross proceeds from sales under the new agreement.","Shares will be sold under existing shelf registration statement; prospectus supplement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88439021.79006606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}